Roger Dansey
Impact in
- Orthopedics and Sports Medicine top 0.2%
- Bone and Joint Diseases
- Oncology top 0.2%
- Bone health and treatments
- Cancer Diagnosis and Treatment
Papers in
Roger Dansey
121 papers receiving 7.4k citations
Hit Papers
Peers
Comparison fields: 5 of 118
- Orthopedics and Sports Medicine 1.8k
- Oncology 5.2k
- Hematology 760
- Rheumatology 1.0k
- Radiology, Nuclear Medicine and Imaging 1.5k
Countries citing papers authored by Roger Dansey
This map shows the geographic impact of Roger Dansey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Dansey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Dansey more than expected).
Fields of papers citing papers by Roger Dansey
This network shows the impact of papers produced by Roger Dansey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Dansey. The network helps show where Roger Dansey may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Roger Dansey, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 130 | |
| 2 | Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab Hit paper breakdown → | 2012 | 495 |
| 3 | 2011 | 67 | |
| 4 | Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study Hit paper breakdown → | 2010 | 1102 |
| 5 | 2008 | 21 | |
| 6 | 2008 | 24 | |
| 7 | 2008 | 40 | |
| 8 | 2005 | 27 | |
| 9 | Randomized double-blind phase 2 study evaluating sameday vs next-day administration of pegfilgrastim with docetaxel, doxorubicin, and cyclophosphamide (tac) in women with early stage and advanced breast cancer | 2004 | 12 |
| 10 | 2000 | 8 | |
| 11 | 1999 | 10 | |
| 12 | 1997 | 13 | |
| 13 | 1995 | 23 | |
| 14 | 1994 | 11 | |
| 15 | 1993 | 5 | |
| 16 | 1990 | 11 | |
| 17 | 1990 | 16 | |
| 18 | 1990 | 5 | |
| 19 | 1988 | 13 | |
| 20 | 1988 | 34 |
About Roger Dansey
Roger Dansey is a scholar working on Oncology, Genetics, Hematology, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging, having authored 122 papers that have together received 7.6k indexed citations. Recurring topics across this work include Bone health and treatments (43 papers), Chronic Lymphocytic Leukemia Research (27 papers), Lymphoma Diagnosis and Treatment (25 papers), Radiopharmaceutical Chemistry and Applications (22 papers), Prostate Cancer Treatment and Research (17 papers), Cancer Treatment and Pharmacology (16 papers), Hematopoietic Stem Cell Transplantation (12 papers) and Neutropenia and Cancer Infections (12 papers). The work is most often cited by research in Orthopedics and Sports Medicine (1.8k citations), Oncology (5.2k citations), Hematology (760 citations), Rheumatology (1.0k citations) and Radiology, Nuclear Medicine and Imaging (1.5k citations). Roger Dansey has collaborated with scholars based in United States, South Africa and France. Frequent co-authors include Qi Jiang, Susie Jun, Karim Fizazi, Neal D. Shore, Janet E. Brown, Alison Stopeck, Carsten Goessl, Ronaldo Damião, Matthew R. Smith and Michael Rader. Their work appears in journals such as Journal of Clinical Oncology, Blood, Oncology, Cancer and Bone.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.